Introduction
Angiogenesis, the growth of new capillaries from preexistent blood vessels, is a complex process which, with few exceptions (i.e., during the female reproductive cycle), does not take place in the adult organism (for reviews, see Risau, 1997; Beck and D'Amore, 1997) . Active angiogenesis is observed, however, in several pathological conditions such as neoplasia and chronic in¯ammatory diseases (Folkman, 1995) . Angiogenesis involves several steps ®nely regulated by the balance of positive and negative factors (Folkman, 1995) . Among the cytokines with positive angiogenic properties, the vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is a speci®c growth factor for endothelial cells and has been implicated as one of the major angiogenesis factors during embryonic development and neoplasia (for review, see Klagsbrun and D'Amore, 1996; Ferrara, 1996) . VEGF/VPF (VEGF-A), a member of a gene family which also includes VEGF-B, VEGF-C and PIGF, is a dimeric glycoprotein present in three major isoforms generated through alternative splicing. Isoforms 165 and 189 (164 and 188 in the mouse, referring to the number of amino acids) posses a heparin binding domain that is not present in the shortest isoform, 121 (120 in the mouse). VEGF isoforms 121 and 165 are released, while VEGF 189 , although being secreted, is retained adhered to the cell surface (Houck et al., 1991) . Regulation of VEGF expression is a complex process mediated by several stimuli, among them hypoxia (Shweiki et al., 1992; Goldberg and Schneider, 1994; Mukhopadhyay et al., 1995) or ras oncogene activation (Grugel et al., 1995; Rak et al., 1995; Larcher et al., 1996; Arbiser et al., 1997) appear as major modulators.
Overexpression of VEGF has been found in angiogenic processes of skin; physiologically in wound healing (Brown et al., 1992) , and in several pathological non-neoplastic conditions such as psoriasis (Detmar et al., 1994) and bullous diseases . These studies showed that the epidermis is the main source for VEGF production in skin. In addition, VEGF expression by keratinocytes in vitro has also been reported (Ballaun et al., 1995; Frank et al., 1995; Detmar et al., 1995) . Keratinocyte-derived VEGF thus appears as a major angiogenic factor for the skin (Detmar, 1996) . We have recently demonstrated increased VEGF expression in mouse epidermal tumors induced by a two-stage, DMBA-TPA (dimethylbenzanthracene-tetradecanoyl phorbol acetate) protocol. Overexpression of VEGF was demonstrated not only in fully malignant tumors but in the premalignant papilloma. We have also shown that VEGF overexpression in this model is associated with H-ras activation, the putative initiating event . Moreover, skin carcinogenesis performed in c-fos null mice gives rise to poorly developed papillomas that express low levels of VEGF and are unable to progress to carcinoma (Saez et al., 1995) . These ®ndings prompted us to speculate that angiogenesis may be critical, not only as a nourishing factor for rapidly growing tumor cells at advanced stages of malignancy, but as a necessary event for tumor development and progression.
To address the relevance of VEGF in vivo for cutaneous angiogenesis as well as its role in the development and progression of epidermal tumors, we have generated transgenic mice that overexpress mouse VEGF 120 under the control of a keratin promoter which is inducible in the suprabasal compartment of the hyperproliferative epidermis and in epidermal tumors. In this study we describe the dramatic phenotype caused by high VEGF expression and demonstrate that VEGF induction leads to accelerated tumor appearance and altered tumor phenotype.
Results

Generation of K6s-VEGF transgenic mouse lines
To direct the expression of VEGF 120 to the epidermis of transgenic mice we used a truncated 2.4 kb fragment of the bovine keratin K6 gene regulatory region (Blessing et al., 1987; Ramirez et al., 1995) . The construct used is outlined in Figure 1a . We and others have shown that this keratin K6 gene regulatory fragment is appropriate to drive gene expression, in an inducible manner, to the suprabasal cell compartment of hyperproliferative epidermis and epidermal tumors (Ramirez et al., 1998; Fowlis et al., 1996; Cui et al., 1996) . Three founder mice (called V2, V27 and V208) were identi®ed by Southern blot analysis of DNA from tail biopsies ( Figure 1b) . As expected from the inducible nature of transgene expression, no apparent phenotype was observed in V27 and V208 mice. However, founder mouse V2 showed scattered erythema throughout the skin during the ®rst few days of life which gradually disappeared with age. Transmission of the transgene to the ospring of this founder mouse did not occur at the expected mendelian rate, since only 11 out of 180 newborn mice were transgenic. These animals developed a striking phenotype. The higher transgene hybridization signal found in the transgenic V2 ospring as compared to that of the founder ( Figure  1b) , together with the low frequency of transgene transmission and the severity of the phenotype in V2 F 1 mice but not in the founder, implies that integration of transgenic DNA in V2 founder has occurred in a mosaic pattern.
High constitutive expression of VEGF leads to a lethal phenotype
The transgenic ospring of founder V2 showed a dramatic phenotype consisting of reddened skin, marked swelling and death within 1 ± 2 days after birth (data not shown). Swelling was a consequence of severe edema since approximately 30% of total body weight of transgenic animals corresponded to the subcutaneous accumulation of exudative¯uid. Although we expected the transgene to be silent, we found that expression occurred in skin at birth, as detected by Northern blot analysis in animals of lines V27 and V2 (Figure 2a ). This is consistent with the observation that K6 is focally induced perinatally. The severity of the phenotype displayed by V2 F 1 mice correlated with the level of constitutive mRNA expression of the transgene (Figure 2a ) as well as with transgene copy number (Figure 1a) . After reprobing the blot with a probe speci®c for the mouse VEGF receptor¯k-1, a band of approximately 6 kb corresponding to¯k-1 mRNA (Matthews et al., 1991) was detected in transgenic V2 F 1 mouse skin but was absent in the skin of V27 pups and control littermates (Figure 2a ) This provides molecular evidence that angiogenesis takes place in the skin of these transgenic mice. The expression of¯k-1 mRNA implies either activation and/or increase in blood vessel density in the tissue.
To de®ne the localization of the transgene expression, immuno¯uorescence staining was performed in the skin of V2F 1 pups, using an anti-VEGF antibody. Positive staining occurs predominantly in the epidermis at the suprabasal level (Figure 2c ). This pattern of transgene expression is consistent with previous reports from our laboratory using a LacZ transgene driven by the 2.4 kb fragment of the keratin K6 promoter (Ramirez et al., 1998) as well as work from another group expressing TGFb with the same promoter .
Histological alterations in the skin of line V2: hypervascularization and edema As expected from the macroscopic appearance of transgenic pups of line V2, histological examination of the skin demonstrated a dramatic increase in the number of blood vessels, particularly in the subepidermal location. Vessels were dilated and ®lled with blood ( Figure 3b ). Due to the severity of the edema, the dermal structure was disrupted and the epidermis appeared hypoplastic as compared to the hyperplastic epidermis, characteristic of normal newborn mice ( Figure 3a ). The number of hair follicles was also highly reduced in the skin of transgenic animals ( Figure 3b ). Immuno¯uorescence analysis using an anti-mouse CD31/PECAM monoclonal antibody, a marker for endothelial cells, also revealed a network of atypical, tortuous blood vessels ( Figure 3d ). These are characterized by a markedly increased diameter of the vascular lumen and increased vessel density as compared with the fewer and narrower capillaries observed in the skin of control animals ( Figure 3c ). This picture is reminiscent of that shown when a transgenic-like approach was used through in vivo retroviral transduction of a VEGF 120 in avian embryo (Flamme et al., 1995) .
Hyperproliferation-associated inducibility of the transgene in lines V27 and V208
Several hyperproliferative stimuli are capable of inducing the transcription of keratin K6 (Schweizer, 1993) . As mentioned above, the 2.4 kb K6 regulatory region has been shown to be competent for transgene inducibility in the skin under hyperproliferative conditions Cui et al., 1996; Ramirez et al., 1998) . Despite low expression at birth, the transgene was completely shut o in adult animals of lines V27 and V208. As expected, a single topical application of the strong tumor promoter TPA that results in hyperplasia, was sucient to induce the transcription of the transgene (Figure 4a ). We have also demonstrated transgene inducubility by wound healing (tape stripping) and by subcutaneous EGF injection in newborn transgenic pups (data not shown). A signi®cant increase in cutaneous vessel density and lumen diameter was detected in transgenic animals of both lines after four applications of TPA as detected by CD31 immunostaining (Figure 4b and c).
Accelerated papilloma development and altered tumor phenotype in double K6sVEGF/TG.AC transgenic mouse
To determine whether overexpression of VEGF in epidermis could in¯uence tumor development and progression response, we performed skin carcinogenesis in the F 1 crosses of K6sVEGF transgenics (line 208) with a transgenic strain (TG.AC) carrying a v-Hras transgene which acts as a classical initiation event (Leder et al., 1990) . Mice carrying the TG.AC transgene develop papillomas without the need for chemical initiation and are very sensitive to a variety of tumor promoters (Leder et al., 1990; Spalding et al., 1993; Hansen and Tennant, 1994) . Line 208 was selected because of its higher VEGF expression (Figure 4a ). The results of this experiment demonstrate that the appearance of premalignant papillomas occurred earlier in the double transgenics (Figure 5a ). The ®rst detectable tumors (larger than 3 mm in diameter) appeared during the third week of TPA treatment. By 5 weeks, 60% of the transgenic animals (eight of 14) had tumors, while no tumors had developed in control mice. Only at the end of ®fth week did tumors begin to appear in control animals (three of 18). The incidence of tumors at week 11 and thereafter was slightly higher in the double transgenics than in the controls. To compare tumor burden between transgenic and control animals, we measured the weight of the total tumor mass corresponding to ®ve animals of each group after 18 weeks of treatment start. The tumor mass of transgenic mice was signi®cantly higher (Figure 5b) . Because of the large tumor load, the remaining transgenic animals had to be sacri®ced at 25 weeks after the ®rst TPA application in accordance to current standards of animal care. When tumors from control and transgenic animals were studied after 6 weeks of TPA treatment, macroscopic and histological dierences were apparent. Most tumors in K6sVEGF animals showed a shiny red, cyst-like appearance, while those that developed in controls were smaller and presented a typical opaque pink, papillomatous shape (data not shown). The size of the great majority of tumors at any given time point was larger in K6sVEGF mice than in controls. Histological examination of tumors from transgenic animals revealed that the tumoral mass is rich in a highly vascular, edematous stroma. In contrast, tumors from control mice showed a less prominent ®brous stroma (Figure 6a and b) . Tumors from transgenic mice at 4 ± 8 weeks were often exudative and bled upon minimal abrasion, e.g., scratching. To seek a causal relationship between the kinetics of tumor appearance and cell proliferation, we performed BrdU incorporation experiments in early papillomas of both control and transgenic animals. While no apparent dierences were found in the BrdU labeling of the epidermal compartment, the number of labeled endothelial cells was much higher in transgenic tumors, re¯ecting the highly active angiogenic process taking place in transgenic papillomas (Figure 6c and d) .
To assess for dierences in progression towards malignancy, we studied the expression of several proteins known to be altered during mouse skin carcinogenesis. As expected, expression of the hyperproliferation-associated keratin K6 apperared highly induced in a continuous pattern in both transgenic and control tumors (Figure 7a and b) . Aberrant expression of keratin K13, a marker for progression in mouse skin carcinogenesis (Nischt et al., 1988; Gimenez-Conti et al., 1990) , was observed in both types of tumors. At 6 weeks, most transgenic tumors show continuous K13 expression, while control tumors show focal staining (Figure 7c and d) . At 11 weeks, transgenic and control tumors presented mostly continuous K13 expression (data not shown). However, in tumors of 6 weeks, we observed partial co-expression of K13 and keratin K1 (data not shown). In the two-stage mouse skin Figure 4 Transgene inducibility and increased vascularization in skin of K6sVEGF mice. Animals of lines V27 and V208 were treated with a single topical application of TPA (+) or treated with acetone (7) (a). After 24 h, total RNA was extracted and analyzed by Northern blot using a murine VEGF cDNA probe. Endogenous VEGF message (endo) is observed as a larger size band. RNA loading was controlled by rehybridization with a GAPDH probe. Immuno¯uorescence staining (CD31) of blood vessels from skins of control (b) and V208 (c) mice treated four times with TPA. Magni®cation, 1206 carcinogenesis model, expression of keratin 1 decreases throughout progression (Aldaz et al., 1988) and excludes K13 positive areas (Gimenez-Conti et al., 1990) .
A number of studies have correlated changes in the expression patterns of a6b4 integrin with an altered risk for malignant conversion (Gomez et al., 1992; Tennembaum et al., 1993; . We therefore also examined expression of a6 in agematched tumors of transgenic and control mice. In 6-week papillomas, dierences in a6 expression were apparent. Strong staining was observed in basal and Figure 7 Immuno¯uorescence study of tumor progression markers and blood vessels in tumors from K6sVEGF mice. Keratins K6, K13, a6 integrin, loricrin and CD31 expression was studied by immuno¯uorescence in frozen sections of tumors at 6 weeks of treatment. High induction of keratin K6 takes place both in control (a) and transgenic (b) tumors in a continuous pattern of staining. Focal K13 staining (orange-red) and scattered blood vessels (green, CD31 staining) in a control tumor (c) Continuous K13 staining and dense vascularization in a transgenic tumor (d). Loricrin expression (red staining) occurs in the very suprabasal strata of tumors and at the granular layer of hyperplastic adjacent skin of both, control (e) and transgenic animals (f). DAPI staining (blue-violet) indicates the position of nuclei to locate the loricrin staining. Basal and suprabasal a6 staining in tumors of transgenic animals (h) as compared to the mainly basal staining in control tumors (g). suprabasal cells of transgenic tumors whereas mainly basal cells were positive for a6 in control tumors (Figure 7g and h) . Previous reports have demonstrated that expression of a6b4 integrin is extended from being predominantly basal to include suprabasal cells in high risk tumors (Gomez et al., 1992; Tennembaum et al., 1993) . At 11 weeks, both control and transgenic papillomas showed basal and suprabasal staining with the anti-a6 antibody (data not shown). Loricrin, a marker for terminal dierentiation, was also included in this study. Expression of this late product showed no dierences between papillomas of control and transgenic animals (Figure 7e and f) since in both cases loricrin-positive cells were found in the more dierentiated strata.
Despite early and continuous K13 expression as well as suprabasal a6 staining in tumors of transgenic mice, we detected no signs of concomitant dysplastic changes, as occurs in the case of tumors induced by two-stage DMBA/TPA carcinogenesis (Aldaz et al., 1987) . Moreover, most papillomas of transgenic mice evolved towards very large, dierentiated and keratinized lesions that progressed no further to malignancy at week 25 when the experiments was discontinued due to the excessive tumor burden.
Discussion
A large body of evidence sustains that angiogenic stimulus in normal and pathologic skin is derived from the avascular epidermis (Malhotra et al., 1989; Detmar, 1996) . One of the mechanisms for enhancing the dermal blood supply to match the oxygen and nutrient requirements associated with hyperproliferation in wound healing, psoriasis, or neoplasms is the overexpression of the angiogenic factor VEGF (Detmar, 1996) . In this report, we show that epidermal overexpression of VEGF using a transgenic approach has, in fact, profound eects on the cutaneous, dermal vasculature.
Physiological levels of VEGF appear to be critically regulated, as even a partial reduction of this factor during development is sucient to cause fetal lethality, as demonstrated in VEGF knock-out mice at hemizygocity (Carmeliet et al., 1996; Ferrara et al., 1996) . On the other hand, we show here that a high, constitutive epidermally-derived overexpression of VEGF also leads to a lethal phenotype characterized by increased vascularization and severe edema possibly due to the extent of vascular hyperpermeability. In addition to the high transgene expression in V2 F 1 mice, the severity of the phenotype may be the result of overexpressing the mouse VEGF 120 , which appears to be the most potent isoform both in the rabbit cornea angiogenesis assay (Morbidelli et al., 1998) . Moreover, when MCF-7 cells were transfected with the dierent VEGF isoforms, VEGF 120 expressing cells showed the higher angiogenic response after being transplanted to nude mice (M Ziche, University of Florence, Italy and R Bicknell, University of Oxford, UK; personal communication). In spite of these in vitro assays, little was known about the function of the non-heparin-binding mVEGF 120 isoform in vivo. Its constitutive overexpression in our transgenic mice led to the formation of a lacunary vascular plexus with remarkably increased vessel density and permeability. In this regard, our results concur with those reported recently using avian embryos transduced with a retrovirus bearing a VEGF 120 cDNA (Flamme et al., 1995) .
Other alterations found in the skin of transgenic animals of line V2, such as epidermal hypoplasia, dermal disruption and decreased number of hair follicules, are probably the consequence of the extreme edema and blood stasis that take place in the highly dilated capillaries. The whole skin picture is reminiscent of that shown recently for the K14-VEGF-C transgenic mouse, although in those animals, the dilated and probably hyperpermeable vessels were of lymphatic origin . It has been shown, however, that proteolytic processing of VEGF-C also confers activity of this molecule through VEGFR 2 (Flk-1) signaling , which may exert some of the eects of VEGF-A.
We have recently shown that VEGF is a relevant factor in mouse skin carcinogenesis and that the VEGF upregulation level correlates with tumor progression stage and activated H-ras dose. A similar pattern of progressive VEGF upregulation pattern was recently described in a K14-HPV16 transgenic model of mouse skin carcinogenesis (SmithMcCune et al., 1997) . To further assess whether overexpression of VEGF in skin could modify the tumor development and/or progression response we performed skin carcinogenesis in the F 1 progeny of crosses of TG.AC with the VEGF inducible transgenic line 208. The results of this experiment showed a clear dependency on angiogenesis for appearance of papillomas, as these lesions developed earlier in the double transgenics. This result has important implications since, in addition to the established knowledge of angiogenesis as a late-in-progression event related to invasion (Hannahan and Folkman, 1996) , we show that the development of premalignant lesions is accelerated in an angiogenic environment. To investigate the mechanism(s) whereby VEGF accelerated tumor development we performed a BrdU incorporation experiment in size-matched early papillomas, which showed that the dierent kinetics of tumor appearance between control and transgenic animals could not be attributed to dierences in epidermal cell proliferation. In contrast, the number of both, proliferating and non proliferating capilary endothelial cells was highly increased in transgenic tumors. A recent report hypothesizes that angiogenic endothelial cells modulate the mesenchymaepithelium environment to enhance tumor invasion, since antibodies against the VEGF receptor¯k-1 inhibit this process (Skobe et al., 1997) . The same group has previously shown that endothelial cells can act as a feeder layer for human primary keratinocyte growth in culture (Smola et al., 1993) . We have also observed that conditioned medium from cultured endothelial cells supports keratinocyte growth (Del Rio et al. unpublished observations) . We thus speculate that the step from epidermal hyperplasia to exophytic lesion (i.e., papilloma) may be governed by the mesenchymaepithelial interaction modulated by the angiogenic environment. In this respect, we have recently shown that, in two-stage carcinogenesis in the SENCAR mouse, the burst of angiogenesis and VEGF production occurs at early papilloma formation (Larcher et al., 1996, Bolontrade M and Conti CJ, manuscript submitted) .
The expression of markers, such as K13 and a6 integrin, at early time points of tumor development suggests that tumors of transgenic animals may be considered papillomas with a high risk for progression to malignancy according to the model of Yuspa and coworkers (1994) . However, the lack of dysplastic signs and the evolution of these tumors towards large, highly keratinized lesions suggest that the expression of the progression markers points to the events leading to the rapid formation of the papilloma, rather than to bona ®de progression to malignancy. In fact, the coexpression of K1 and K13 in the transgenic, but no in control tumors, also support this conclusion. The cause of the formation of the large, keratinized lesions responsible for the increased tumor burden, remain to be determined. It is conceivable that excesive VEGF expression results in abnormal vascularization and/or insucient stroma remodeling which may interfere with the development of the fully malignant phenotype. A de®nitive role of VEGF overexpression for papilloma conversion could not be assessed in this study because the experiments were discontinued at week 25 due to excessive tumor burden. At this time point, no carcinomas were observed in either transgenic or in control animals. Therefore, we are currently using other approaches such as back crossing the transgenic mice to p53 null background, to carry out tumor experiments under conditions that favor papilloma conversion.
Our study con®rms previous reports showing that suprabasal cells are highly ecient for secretion of paracrine growth factors, such as TGF-b or TGF-a (Wang et al., 1995) , in transgenic mice. Since suprabasal cells develop later than basal cells during embryogenesis, their targeting for transgenic and gene therapy approaches, is probably less critical to epidermal physiology allowing the expression of genes which otherwise would be lethal. For instance, the possibility of having genetically-modi®ed human keratinocytes to produce VEGF and other angiogenic factors driven by an inducible suprabasal promoter would be highly bene®cial for the treatment of slowhealing, poorly vascularized cutaneous lesions. Our transgenic mice are an useful in vivo model for addressing the feasibility of such an approach. In summary, we have generated a transgenic model to study the angiogenic process and its relevance in carcinogenesis as well as its potential in experimental therapeutic for other cutaneous pathologies.
Materials and methods
Plasmid construction and generation of transgenic mice
The cDNA of the VEGF 120 was excised as a EcoRI fragment from plasmid pVEGF2 (Breier et al., 1992) and introduced in the polylinker of the vector p163/7 (Woodroofe et al., 1992) as previously described (Murillas et al., 1995; Robles et al., 1996) . The SalI/KpnI fragment containing the 5' bglobin intron 2, the cDNA and the 3' polyadenylation sequences was inserted 3' downstream of the 2.4 kb fragment of the bovine keratin K6 regulatory sequences (Ramirez et al., 1995) cloned in pBluescript. This construct was designated pK6sVEGF. The transgene was excised from the plasmid pK6sVEGF with NotI/Asp718 restriction enzymes, puri®ed by low melting point agarose electrophoresis and Elutip columns (Schleicher and Schuell), adjusted to a ®nal concentration of approximately 2 mg/ml and microinjected into (C57BL/66DBA/2) F 2 mouse embryos as described (Hogan et al., 1986) . Founder mice were identi®ed by Southern blot analysis of tail DNA, using the 2.4 kb fragment corresponding to the truncated bovine keratin K6 promoter as a probe.
RNA blot analysis
Total RNA was extracted from skin samples by the acidguanidinium method (Chomczynsky and Sacchi, 1987) . RNA (15 mg per lane) was electrophoresed through a 1% agarose gel containing 6% formaldehyde and transferred to a nylon membrane (Gene Screen Plus, DuPont) by capillarity in 106 standard saline citrate (SSC) (16SSC=0.15 M NaCl and 0.015 M sodium citrate). The ®lter was ultraviolet-irradiated for 2 min, baked for 2 h at 808C and hybridized to 32 P random-primer labeled probes speci®c for mouse VEGF (Breier et al., 1992) , VEGFR2 (¯k-1) isolated by PCR using published primers (Fong et al., 1995) or a 1.3 kb PstI fragment of rat GAPDH cDNA.
Histological analysis
Skin and tumor samples were ®xed in formaldehyde (10% in phosphate-buered saline) and embedded in paran. Sections were cut at 5 mm and stained with hematoxylineosin.
Immuno¯uorescence
Immunodetection of blood vessels was carried out by staining 7 mm frozen sections of skin and tumors with a rat monoclonal antibody against mouse CD31 (Pharmingen, La Jolla, Ca). VEGF was detected by staining with a polyclonal anti VEGF antiserum (A-20, Santa Cruz, Santa Cruz, Ca). Keratins K13, K1 and loricrin were detected with monospeci®c polyclonal antisera (a generous gift of Dr Dennis Roop, Baylor College of Medicine, Houston, Texas) a6 integrin was detected with a rat mAb provided by Dr Guido Tarone (made available through Dr Dirk Breitkeutz, DKFZ, Heidelberg, Germany) Secondary antibodies were FITC-labeled anti-rat IgG (for CD31 and alpha 6) and anti-rabbit IgG coupled to Texas red (Jackson ImmunoResearch Laboratories).
TPA treatments and tumor experiments
Hemizygous VEGF transgenic animals (males and females) from line V208 were bred with homozygous TG.AC mice (Leder et al., 1990 ) (Charles River). Double transgenics (n=14) were identi®ed by Southern blot and caged separately from hemizygous TG.AC not carrying the VEGF transgene (n=18). These animals were used as control. Double transgenic and controls were treated twice weekly with topical applications of 5 mg of TPA in 200 ml of acetone for 7 weeks according to standard protocols (Hansen and Tennant, 1994) . To determine transgene inducibility, mice were treated with a single topical application of TPA (5 mg) and skins were collected 24 h later for RNA extraction. Twice weekly applications of TPA (5 mg) for 2 weeks were carried out to assess transgene-induced vascularization.
BrdU incorporation assay
Two hours before sacri®ce tumor-bearing animals were injected i.p. with BrdU (20 mg/kg) in saline (0.9% NaCl). Brdu-labeled cells were detected in sections from paran embedded tumor using a commercial kit .
